Exploring the Need for More Comprehensive Biomarker Testing in Early-Stage NSCLC

Biomarker testing in non-small cell lung cancer is underutilized, hindering optimal treatment. Streamlined processes and education are vital for improvement.

Experts discuss the underutilization of biomarker testing in metastatic lung cancer, emphasizing the need for reflexive testing and improved communication.

Experts discuss the underutilization of biomarker testing in metastatic lung cancer, emphasizing the need for improved testing strategies and healthcare access.

A 62-year-old woman with stage IIIA lung cancer faces complex diagnostic and treatment decisions, highlighting the importance of multidisciplinary evaluation.

This case examines effective management of early-stage non–small cell lung cancer (NSCLC) requiring integrating imaging, laboratory results, and molecular profiling to guide therapy.

This segment examines optimal care for patients with early-stage non–small cell lung cancer (NSCLC) relying on coordinated multidisciplinary collaboration.